Drug Profile
Eniluracil - Processa Pharmaceuticals
Alternative Names: 5-Ethynyluracil; 5-EU; 776C85; ADH 300004; GW 776C85; NGC-Cap; NGC-Capecitabine; PCS-6422Latest Information Update: 18 Apr 2024
Price :
$50
*
At a glance
- Originator GlaxoSmithKline
- Developer Adherex Technologies; Fennec Pharmaceuticals; GlaxoSmithKline; Processa Pharmaceuticals
- Class Antineoplastics; Chemosensitisers; Pyrimidinones; Small molecules
- Mechanism of Action Dihydropyrimidine dehydrogenase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase I Breast cancer; Colorectal cancer; Gastrointestinal cancer; Liver cancer; Pancreatic cancer; Solid tumours
- Preclinical Chemotherapy-induced damage
- Discontinued Erythrodysaesthesia; Head and neck cancer; Prostate cancer
Most Recent Events
- 11 Apr 2024 Updated adverse events and pharmacokinetics data from a phase-Ib trial in Gastrointestinal cancer was released by Processa Pharmaceuticals
- 25 Jan 2024 Updated adverse events and efficacy data from a phase-Ib trial in Gastrointestinal cancer was released by Processa Pharmaceuticals ,
- 25 Jan 2024 Processa Pharmaceuticals completes a phase-Ib trial in Gastrointestinal cancer in USA ,